In this podcast, Rakesh Jain, MD, MPH, examines the similarities and differences between the 2 medications approved by the US Food and Drug Administration for the treatment of tardive dyskinesia.
In this podcast, Rakesh Jain, MD, MPH, examines the similarities and differences between the 2 medications approved by the US Food and Drug Administration for the treatment of tardive dyskinesia.
Listen to a discussion on the importance of sleep in the production of body homeostasis and the glymphatic system's ability to drain buildup of toxins in the brain.
Listen to a discussion on the importance of sleep in the production of body homeostasis and the glymphatic system's ability to drain buildup of toxins in the brain.
In this episode, Rachel Marie E. Salas, MD, MEd, continues her conversation with C. Debbie Lin, MD, discussing some of the major challenges in neurology private practice, balancing work with other aspects of her life, and the career advice...
In this episode, Rachel Marie E. Salas, MD, MEd, continues her conversation with C. Debbie Lin, MD, discussing some of the major challenges in neurology private practice, balancing work with other aspects of her life, and the career advice...
In this episode, Rachel Marie E. Salas, MD, MEd, talks with with C. Debbie Lin, MD, to discuss why she pursued private practice and the excitement she finds in practicing as a general neurologist.
In this episode, Rachel Marie E. Salas, MD, MEd, talks with with C. Debbie Lin, MD, to discuss why she pursued private practice and the excitement she finds in practicing as a general neurologist.
In this episode, Rachel Marie E. Salas, MD, MEd, continues her conversation with Mark J. Milstein, MD, FAAN, to discuss how he discovered his interest in medical education and future trends in neurology training.
In this episode, Rachel Marie E. Salas, MD, MEd, continues her conversation with Mark J. Milstein, MD, FAAN, to discuss how he discovered his interest in medical education and future trends in neurology training.
In this episode, Rachel Marie E. Salas, MD, MEd, wraps up her conversation with Mark J. Milstein, MD, FAAN, with details on his advocacy work through the American Medical Association and the American Academy of Neurology, and how neurologists...
In this episode, Rachel Marie E. Salas, MD, MEd, wraps up her conversation with Mark J. Milstein, MD, FAAN, with details on his advocacy work through the American Medical Association and the American Academy of Neurology, and how neurologists...
In this episode, Rachel Marie E. Salas, MD, MEd, talks with Mark J. Milstein, MD, FAAN, to discuss his hybrid clinical work as a neurohospitalist and neuromuscular specialist at Montefiore Medical Center in the Bronx, New York.
In this episode, Rachel Marie E. Salas, MD, MEd, talks with Mark J. Milstein, MD, FAAN, to discuss his hybrid clinical work as a neurohospitalist and neuromuscular specialist at Montefiore Medical Center in the Bronx, New York.
In this episode, Rachel Marie E. Salas, MD, MEd, continues her conversation with Madhu Mona Soni, MD, FAAN, to discuss future trends in neurology, wellness in the workplace, and telehealth.
In this episode, Rachel Marie E. Salas, MD, MEd, continues her conversation with Madhu Mona Soni, MD, FAAN, to discuss future trends in neurology, wellness in the workplace, and telehealth.
In this episode, Dr Rachel Salas, MD, MEd, sits down with Madhu Mona Soni, MD, FAAN, to discuss exciting developments in neuromuscular neurology, the power of interdisciplinary patient care, and more!
In this episode, Dr Rachel Salas, MD, MEd, sits down with Madhu Mona Soni, MD, FAAN, to discuss exciting developments in neuromuscular neurology, the power of interdisciplinary patient care, and more!
In this episode, Rachel Marie E. Salas, MD, MEd, interviews Marie Eugene, DO, about her work in medical education and training, what being an epilepsy specialist involves, and new developments in epileptology.
In this episode, Rachel Marie E. Salas, MD, MEd, interviews Marie Eugene, DO, about her work in medical education and training, what being an epilepsy specialist involves, and new developments in epileptology.
In July, Teva announced positive results in a phase 3 trial of migraine medication Ajovy (fremanezumab) for children and adolescents, making it the first anti-CGRP (calcitonin gene-related peptide) monoclonal antibody to be effective in this...
In July, Teva announced positive results in a phase 3 trial of migraine medication Ajovy (fremanezumab) for children and adolescents, making it the first anti-CGRP (calcitonin gene-related peptide) monoclonal antibody to be effective in this...
Compared with moderate-dose therapy, high-dose statin therapy in patients with mild ischemic stroke did not decrease the risk of stroke recurrence and was associated with an increased risk of intracranial hemorrhage over 12 months.
Compared with moderate-dose therapy, high-dose statin therapy in patients with mild ischemic stroke did not decrease the risk of stroke recurrence and was associated with an increased risk of intracranial hemorrhage over 12 months.
Regardless of their neurologic condition, patients rated outpatient teleneurology appointments as highly acceptable, according to a study published in the Journal of Neurology.
Regardless of their neurologic condition, patients rated outpatient teleneurology appointments as highly acceptable, according to a study published in the Journal of Neurology.
The US FDA approved an indication expansion for the gene therapy Elevidys (delandistrogene moxeparvovec-rokl) to include patients with Duchenne muscular dystrophy (DMD) with a confirmed mutation in the DMD gene who are nonambulatory and 4...
The US FDA approved an indication expansion for the gene therapy Elevidys (delandistrogene moxeparvovec-rokl) to include patients with Duchenne muscular dystrophy (DMD) with a confirmed mutation in the DMD gene who are nonambulatory and 4...
Backward walking speed reserve, or the difference between an individual’s preferred and maximal backward walking speed, was associated with disease severity in patients with multiple sclerosis (MS).
Backward walking speed reserve, or the difference between an individual’s preferred and maximal backward walking speed, was associated with disease severity in patients with multiple sclerosis (MS).
VYVGART Hytrulo (efgartigimod alfa/hyaluronidase) was recently approved by the Food and Drug Administration (FDA) for the treatment of adults with chronic inflammatory demyelinating polyneuropathy (CIDP).
VYVGART Hytrulo (efgartigimod alfa/hyaluronidase) was recently approved by the Food and Drug Administration (FDA) for the treatment of adults with chronic inflammatory demyelinating polyneuropathy (CIDP).
Male individuals who engage in moderate physical activity and fitness may lower their risk for amyotrophic lateral sclerosis (ALS) later in life, according to study findings published in Neurology.
Male individuals who engage in moderate physical activity and fitness may lower their risk for amyotrophic lateral sclerosis (ALS) later in life, according to study findings published in Neurology.
The US Food and Drug Administration (FDA) recently approved Wakix (pitolisant) for the treatment of excessive daytime sleepiness in pediatric patients 6 years and older with narcolepsy, US maker Harmony Biosciences announced.
The US Food and Drug Administration (FDA) recently approved Wakix (pitolisant) for the treatment of excessive daytime sleepiness in pediatric patients 6 years and older with narcolepsy, US maker Harmony Biosciences announced.
Chronic loneliness was associated with higher stroke risk, independent of other factors, according to recent prospective cohort study results published in eClinicalMedicine.
Chronic loneliness was associated with higher stroke risk, independent of other factors, according to recent prospective cohort study results published in eClinicalMedicine.
The calcitonin gene-related peptide inhibitor atogepant reduced monthly migraine and headache days, as well as days using pain medication, in patients with chronic migraine with and without acute medication overuse.
The calcitonin gene-related peptide inhibitor atogepant reduced monthly migraine and headache days, as well as days using pain medication, in patients with chronic migraine with and without acute medication overuse.
Early Alzheimer’s Disease: Caregiver Connections, Shared Decision Making, and Patient Resources
To view accreditation information/faculty disclosures for the program, click
Early Alzheimer’s Disease: Caregiver Connections, Shared Decision Making, and Patient Resources
To view accreditation information/faculty disclosures for the program, click
Early Alzheimer’s Disease: Caregiver Connections, Shared Decision Making, and Patient ResourcesTo claim credit for the program, click HERE for the evaluation. You will need to log in or create an account with NACCME, and then click...
Early Alzheimer’s Disease: Caregiver Connections, Shared Decision Making, and Patient ResourcesTo claim credit for the program, click HERE for the evaluation. You will need to log in or create an account with NACCME, and then click...
Emerging Treatments for Early Alzheimer Disease: Efficacy and Safety Data
To view accreditation information/faculty disclosures for the program, click
Emerging Treatments for Early Alzheimer Disease: Efficacy and Safety Data
To view accreditation information/faculty disclosures for the program, click
Emerging Treatments for Early Alzheimer’s Disease: Efficacy and Safety DataTo claim credit for the program, click HERE for the evaluation. You will need to log in or create an account with NACCME, and then click on the evaluation...
Emerging Treatments for Early Alzheimer’s Disease: Efficacy and Safety DataTo claim credit for the program, click HERE for the evaluation. You will need to log in or create an account with NACCME, and then click on the evaluation...
Emerging Treatments for Early Alzheimer’s Disease: Mechanisms of Action
To view accreditation information/faculty disclosures for the program, click
Emerging Treatments for Early Alzheimer’s Disease: Mechanisms of Action
To view accreditation information/faculty disclosures for the program, click
Emerging Treatments for Early Alzheimer’s Disease: Mechanisms of ActionTo claim credit for the program, click HERE for the evaluation. You will need to log in or create an account with NACCME, and then click on the evaluation button...
Emerging Treatments for Early Alzheimer’s Disease: Mechanisms of ActionTo claim credit for the program, click HERE for the evaluation. You will need to log in or create an account with NACCME, and then click on the evaluation button...
Current Treatment Limitations and Clinical Needs in Early Alzheimer’s Disease
To view accreditation information/faculty disclosures for the program, click
Current Treatment Limitations and Clinical Needs in Early Alzheimer’s Disease
To view accreditation information/faculty disclosures for the program, click